AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05426304
Drug: Agomelatine
RxNorm normalized name: agomelatine
DrugBank: Agomelatine (DB06594)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: agomelatine 25 mg/day for 180 days
Trial: NCT04970108
Drug: Empagliflozin + telmisartan
RxNorm normalized name: Empagliflozin
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: EMPAGLIFLOZIN Empagliflozin 25 mg coated tablet. Drug: TELMISARTAN Telmisartan 40/80 mg coated tablet. EGITO PLACEBO Egito placebo coated tablet.
Trial: NCT04993014
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjuvant trastuzumab + pertuzumab (arm B of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline)
Trial: NCT04993014
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjuvant trastuzumab (arm A of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline) Association with pertuzumab in arm B of the 2 cohorts
Trial: NCT05874583
Drug: Combined route administration of Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tranexamic acid in topical route administration
Trial: NCT05874583
Drug: Intravenous route Tranexamic acid injection
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra venous route administration
Trial: NCT04753177
Drug: Ribocyclib, fulvestrant, triptorelin
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
Trial: NCT05795335
Drug: CDK4/6 inhibitor
RxNorm normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitors
Trial: NCT05232084
Drug: Bupivacaine + Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Trial: NCT05112120
Drug: Olumiant
RxNorm normalized name: Olumiant
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olumiant (4mg) will be administered in line with standard of care guidance.
Trial: NCT05937568
Drug: Imetelstat
RxNorm normalized name: Imetelstat
DrugBank: Imetelstat (DB14909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive imetelstat, intravenously (IV) by infusion every 4 weeks.
Trial: NCT00666783
Drug: palonosetron
RxNorm normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: receive a single, intravenous dose of palonosetron 0.25 mg, 30 minutes before receiving highly emetogenic chemotherapy.
Trial: NCT00666783
Drug: Granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: receive a single, intravenous dose of granisetron 3 mg, 30 minutes before chemotherapy.
Trial: NCT05114837
Drug: allogeneic CAR19 regulatory T cells (CAR19-tTreg)
RxNorm normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose administration of CAR19-tTreg
Trial: NCT05114837
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 30 mg/m\^2 is administered as an intravenous (IV) infusion per institutional guidelines once a day on 4 consecutive days (Day -5, Day -4, Day -3 and Day -2)
Trial: NCT05417113
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: liposomal bupivacaine
Trial: NCT05417113
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.25% in ESP blocks
Trial: NCT05053828
Drug: Antiplatelet Drug
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet drugs and agents
Trial: NCT06532942
Drug: (Part A) MKND-201
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single ascending doses (Target Dose, High Dose, and Very High Dose) of MKND-201 or placebo administered via oral inhalation on Day 1
Trial: NCT06532942
Drug: (Part B) MKND-201
RxNorm normalized name: SODIUM CHLORITE 0.0256 kg in 1 kg TOPICAL SPRAY [Chlorsan 105 Part B]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive multiple ascending doses (Target Dose and High Dose) of MKND-201 or placebo administered via oral inhalation, twice daily, from Day 1 to Day 7
Trial: NCT06405217
Drug: Recombinant Human Thyroid Stimulating Hormone
RxNorm normalized name: Recombinant Human Thyroid Stimulating Hormone
DrugBank: Thyrotropin alfa (DB00024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days
Trial: NCT06233084
Drug: Desogestrel-Test product
RxNorm normalized name: desogestrel Oral Product
DrugBank: Desogestrel (DB00304)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desogestrel Tablets 0.075 mg Manufactured by: POND'S CHEMICAL THAILAND R.O.P., Thailand
Trial: NCT06233084
Drug: Desogestrel-Reference product
RxNorm normalized name: desogestrel Oral Product
DrugBank: Desogestrel (DB00304)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desogestrel Tablets 0.075 mg Manufactured by: N.V. Organon, The Netherlands
Trial: NCT05841446
Drug: test apixaban tablets
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: specification: 2.5 mg, manufacturer: Disha Pharmaceutical Group Co., Ltd., Shandong, China
Trial: NCT05841446
Drug: reference apixaban tablets
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: specification: 2.5 mg, manufacturer: Bristol-Myers Squibb Manufacturing Company, USA
Trial: NCT05918224
Drug: Streptococcus salivarius K12
RxNorm normalized name: Streptococcus salivarius
DrugBank: Streptococcus salivarius (DB19274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in intervention group were treated with Streptococcus salivarius K12 lozenges three times a day after gargling from the first day of radiotherapy up to 1 week after the end of treatment. Streptococcus salivarius K12 is dissolved in the mouth and then swallowed.
Trial: NCT05918224
Drug: Streptococcus salivarius K12 simulants
RxNorm normalized name: Streptococcus salivarius
DrugBank: Streptococcus salivarius (DB19274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in control group were treated with Streptococcus salivarius K12 simulants, and its use method and use time are the same as intervention group.
Trial: NCT05940324
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine is an FDA-approved dissociative anesthetic.
Trial: NCT05940324
Drug: Naltrexone Pill
RxNorm normalized name: naltrexone Pill
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone is an oral opioid antagonist approved by the Food and Drug Administration (FDA) to treat both alcohol use disorder (AUD) and opioid use disorder (OUD)
Trial: NCT06007547
Drug: Poractant Alfa
RxNorm normalized name: Poractant alfa
DrugBank: Poractant alfa (DB09113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Poractant alfa (Curosurf) 200mg/kg administered under direct laryngoscopy using a surfactant instillation catheter
Trial: NCT05023382
Drug: Teduglutide
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teduglutide 0.05 mg/kg SC injection
Trial: NCT06182176
Drug: Sulphadoxine-pyrimethamine and Amodiaquine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention drugs are standard drugs approved by the World Health Organisation for the preventive treatment of malaria (sulphadoxine-pyrimethamine and amodiaquine), schistosomiasis (praziquantel) and soil-transmitted helminths (albendazole).
Trial: NCT05277623
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the anhepatic phase, the patients in the mannitol group (30) will receive 1 g/kg
Trial: NCT05351554
Drug: Namilumab
RxNorm normalized name: Namilumab
DrugBank: Namilumab (DB13037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Namilumab administered subcutaneously
Trial: NCT05351554
Drug: Open label Namilumab
RxNorm normalized name: Namilumab
DrugBank: Namilumab (DB13037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Namilumab administered subcutaneously
Trial: NCT05351554
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone or equivalent
Trial: NCT05997979
Drug: Capsaicin 8% patch
RxNorm normalized name: CAPSAICIN 8% PATCH KIT,4
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive Capsaicin 8% patch at the inclusion of the study and three months later if it is necessary (persistant pain). Qutenza should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.
Trial: NCT04600778
Drug: Cavosonstat 5 mg
RxNorm normalized name: Cavosonstat
DrugBank: Cavosonstat (DB14775)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavosonstat (low dose)
Trial: NCT04600778
Drug: Cavosonstat 10 mg
RxNorm normalized name: Cavosonstat
DrugBank: Cavosonstat (DB14775)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavosonstat (medium dose)
Trial: NCT04600778
Drug: Cavosonstat 25 mg
RxNorm normalized name: Cavosonstat
DrugBank: Cavosonstat (DB14775)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavosonstat (high dose)
Trial: NCT04448392
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upon completion of standard of care acyclovir for treatment of neonatal HSV disease, valacyclovir oral suspension (per ASHP recipe), 20 mg/kg every 8 hours, to be given for 2 (up to 7) days
Trial: NCT05154435
Drug: mostcare hemodynamic monitor
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mostcare hemodynamic monitoring integrated into the radial artery catheter. According to the data obtained, intraoperative fluid management was arranged with certain algorithms.
Trial: NCT05227300
Drug: Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
Trial: NCT06345365
Drug: mitoxantrone liposome, Ara-Cytarabine and azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mitoxantrone hydrochloride liposome 24 mg/m2, IV every 4 weeks, day 1; Ara-Cytarabine 100 mg/m2, IV every 12 h, days 1-7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7
Trial: NCT06417736
Drug: Megestrol Acetate 40 MG
RxNorm normalized name: megestrol acetate 40 MG
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 160mg/one time/day
Trial: NCT05813314
Drug: BMN 111 administration via vial and syringe
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BMN 111 Injection will be given using vial and syringe
Trial: NCT04601610
Drug: Ningetinib Tosylate（multi-target TKI）
DrugBank: Ningetinib (DB16256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ningtinib QD, dose will be decided by investigator
Trial: NCT03435718
Drug: Oxfendazole
RxNorm normalized name: Oxfendazole
DrugBank: Oxfendazole (DB11446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension
Trial: NCT03435718
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT00000717
Drug: Primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05228821
Drug: Voxelotor Oral Tablet
RxNorm normalized name: voxelotor Oral Tablet
DrugBank: Voxelotor (DB14975)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: During the Treatment Period, participants will receive 1500 mg of voxelotor once daily (administered as tablets) for 24 weeks in addition to ongoing current standard of care (SOC) treatment
Trial: NCT05583838
Drug: rhTPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: initial therapy: rhTPO s.c, 300 or 600U/kg daily based on baseline platelet count; maintenance therapy: rhTPO s.c, 300 \~ 600U/kg every other day depends on platelet count.
Trial: NCT05583838
Drug: Eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: initial therapy: Eltrombopag oral, 25 or 50mg daily based on baseline platelet count; maintenance therapy: Eltrombopag oral, 25 \~ 75mg daily or every other day depends on platelet count.
Trial: NCT06478264
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100mg/m\^2, intravenous infusion for 1-3 days,21 days/cycle, 4 cycles
Trial: NCT06478264
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg/m\^2 ,intravenous infusion for 1-3 days ,21 days/cycle, 4 cycles
Trial: NCT06478264
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (AUC = 5) on 1 Day,21 days/cycle, 4 cycles ;
Trial: NCT06478264
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200mg adebrelimab was given intravenously on 2 day after chemotherapy,21 days/cycle, continuous use.
Trial: NCT04859621
Drug: Vitamin D3 4000 IU
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
Trial: NCT04859621
Drug: Vitamin D3 2000 IU
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, 1 tablet of each per time, qd, oral administration with the first meal, continuous use for 48 weeks
Trial: NCT04941521
Drug: Exenatide 2 mg [Bydureon]
RxNorm normalized name: exenatide 2 MG [Bydureon]
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide will be purchased commercially as Bydureon® for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 6 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
Trial: NCT05067530
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CDK4/6 inhibitor
Trial: NCT05067530
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy
Trial: NCT05067530
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT05256134
Drug: Gantenerumab
RxNorm normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gantenerumab will be administered as per the dosing schedule described in the Arm description.
Trial: NCT05062902
Drug: Botulinum Neurotoxin
RxNorm normalized name: Botulinum neurotoxin
DrugBank: Equine Botulinum Neurotoxin E Immune FAB2 (DB13897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm).
Trial: NCT05477498
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Application of FCM solution (Ferinject®, Vifor Pharma AG, Villars-sur-Glâne, Switzerland) by intravenous injection.
Trial: NCT05497193
Drug: perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: China's state food and drug administration approved indications for adults and children aged 4 or more focal epileptic hair company or not with secondary comprehensive seizures of epilepsy, adding treatment, in July 2020 to monotherapy without clinical approval, the current domestic perampanel monotherapy clinical effectiveness and safety of focal epilepsy in children have not been reported.
Trial: NCT01157559
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 week prospective study
Trial: NCT06632522
Drug: radiotherapy combined with Camrelizumab and Apatinib
RxNorm normalized name: picodralazine and diuretics, combinations with psycholeptics
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab is administered intravenously (without preventive medication), with a fixed dose of 200mg, with an infusion of 30 min (not less than 20 min and not more than 60 min) every three weeks. Apatinib, 250 mg, taken orally within half an hour after meals, QD, continuously.
Trial: NCT00002149
Drug: Clavulanate potassium
RxNorm normalized name: Clavulanate Potassium
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002149
Drug: Pseudoephedrine hydrochloride
RxNorm normalized name: Pseudoephedrine Hydrochloride
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002149
Drug: Amoxicillin trihydrate
RxNorm normalized name: Amoxicillin Trihydrate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05934955
Drug: BI 1839100
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1839100
Trial: NCT06609343
Drug: Bupropion Hydrochloride 150 MG
RxNorm normalized name: bupropion hydrochloride 150 MG
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion Hydrochloride Extended Release is administered orally three times a week during routine dialysis sessions for 8 consecutive weeks
Trial: NCT04238988
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
Trial: NCT04238988
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy medication
Trial: NCT04238988
Drug: Taxol
RxNorm normalized name: Taxol
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy medication
Trial: NCT06526455
Drug: Vonoprazan
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: oral drug 3-56 days after ESD.
Trial: NCT06526455
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral drug 3-56 days after ESD.
Trial: NCT06297954
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive metoclopramide 20 mg IV in a single dose prior to randomization.
Trial: NCT04860063
Drug: Berberine
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomly assigned to the intervention group will be provided with Berberine 500 mg administrated per os three times a day for six months
Trial: NCT06490614
Drug: Dexmedetomidine in superficial cervical plexus block
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, dexmedetomidine 1 μg/kg (precedex 100mcg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.